TY - JOUR
T1 - Serum biomarker CA 15-3 as predictor of response to antifibrotic treatment and survival in idiopathic pulmonary fibrosis
AU - Moll, Sofia A.
AU - Wiertz, Ivo A.
AU - Vorselaars, Adriane D.M.
AU - Zanen, Pieter
AU - Ruven, Henk J.T.
AU - Van Moorsel, Coline H.M.
AU - Grutters, Jan C.
N1 - Publisher Copyright:
© 2020 Future Medicine Ltd.
PY - 2020/8
Y1 - 2020/8
N2 - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxide (estimates respectively:-5.21 and-4.69; p < 0.001). Baseline and 6-month CA 15-3 above 58.5 (hazard ratio: 1.67; p = 0.031) and 50.5 kU/l (hazard ratio: 2.99; p < 0.001), respectively, showed impaired survival compared with lower levels. Conclusion: CA 15-3 is associated with pulmonary function test during follow-up in IPF on antifibrotic treatment. Higher (follow-up) values are related with poor survival. Therefore, CA 15-3 is a promising follow-up biomarker in IPF.
AB - Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxide (estimates respectively:-5.21 and-4.69; p < 0.001). Baseline and 6-month CA 15-3 above 58.5 (hazard ratio: 1.67; p = 0.031) and 50.5 kU/l (hazard ratio: 2.99; p < 0.001), respectively, showed impaired survival compared with lower levels. Conclusion: CA 15-3 is associated with pulmonary function test during follow-up in IPF on antifibrotic treatment. Higher (follow-up) values are related with poor survival. Therefore, CA 15-3 is a promising follow-up biomarker in IPF.
KW - anti-fibrotic therapy
KW - cancer antigen 15-3
KW - idiopathic pulmonary fibrosis
KW - interstitial lung disease
KW - prognostic biomarker
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85091127620&partnerID=8YFLogxK
U2 - 10.2217/bmm-2020-0165
DO - 10.2217/bmm-2020-0165
M3 - Article
C2 - 32940077
AN - SCOPUS:85091127620
SN - 1752-0363
VL - 14
SP - 997
EP - 1007
JO - Biomarkers in medicine
JF - Biomarkers in medicine
IS - 11
ER -